Inducible Nitric Oxide Synthase inhibits macrophage migration,a potential explanation for iNOS's proatherosclerotic action by Huang, Hua
Aus der Medizinischen Klinik und Poliklinik IV
der Ludwig-Maximilians-Universität München
Direktor: Prof. Dr. med. Martin Reincke
Abteilung Angiologie, Leiter: Prof. Dr. med. Ulrich Hoffmann
Inducible Nitric Oxide Synthase inhibits macrophage migration,
a potential explanation for iNOS's proatherosclerotic action
Dissertation
zum Erwerb des Doktorgrades der Medizin
an der Medizinischen Fakultät der
Ludwig-Maximilians-Universität zu München
vorgelegt von
Hua Huang
aus
Wuhan
2014
Mit Genehmigung der Medizinischen Fakultät
der Universität München
Berichterstatter:
Mitberichterstatter:
Mitbetreuung durch den
promovierten Mitarbeiter:
Dekan:
Tag der mündlichen Prüfung:
Prof. Dr. med. Ulrich Hoffmann
Prof. Dr. med. Hae-Young Sohn
Prof. Dr. med. Andreas Schober
Priv. Doz. Dr. Med. Peter Kuhlencordt
Prof. Dr. med. Dr. h.c. M. Reiser, FACR, FRCR
09.01.2014
1
CONTENTS
CHAPTER I..................................................................................................................3
I. Introduction...............................................................................................................4
I.1. Atherosclerosis..................................................................................................... 4
I.2. Oxidative stress (OS)............................................................................................7
I.3. Reactive oxygen species and vascular disease..................................................... 9
I.4. Nitric oxide synthases (NOS).............................................................................10
I.5. Aims of the investigation....................................................................................15
CHAPTER II...............................................................................................................16
II. Materials and Methods......................................................................................... 17
II.1. Materials............................................................................................................17
II.2. Methods.............................................................................................................20
CHAPTER III............................................................................................................. 27
III. Results...................................................................................................................28
III.1. Migration assay................................................................................................28
III.2. OxLDL regulates expression of iNOS in RAW 264.7 cells.............................38
III.3. iNOS inhibition with 1400W was associated with a reduction in NO and
peroxynitrite formation and an increase in superoxide generation...........................39
III.4. The inhibition of migration was associated with actin polymerization........... 41
III.5. Inhibition of migration was associated with increased phosphorylation of focal
adhesion kinase......................................................................................................... 43
CHAPTER IV............................................................................................................. 45
IV. Discussion.............................................................................................................. 46
2
CHAPTER V...............................................................................................................53
Summary..................................................................................................................... 54
Zusammenfassung......................................................................................................55
References................................................................................................................... 57
Abbreviation............................................................................................................... 68
Acknowledgements.....................................................................................................70
Curriculum Vitae........................................................................................................71
Introduction
3
Chapter I
Introduction
4
I. Introduction
Atherosclerosis is known as one of the leading reasons of death in western
countries[1]. Atherosclerosis is defined by the chronic accumulation of lipids and
fibrous matters in the vessel wall which may lead to progressive stenosis and
reduction of blood flow. The initial step, triggering many of the events leading to
plaque progression, is considered oxidation of low density lipoprotein (ox-LDL) in
the subendothelial space[2].
Nitric oxide synthases (NOS) are the enzymes responsible for generation of nitric
oxide (NO), which is one of the smallest known bioactive products of mammalian
cells[3] and mediates several biological effects[4]. There are three distinct isoforms of
NOS: neuronal NOS (nNOS), inducible NOS (iNOS) and endothelial NOS (eNOS)[5].
The expression of inducible nitric oxide synthase (iNOS) in early and advanced
atherosclerotic human and murine plaques modulates cellular and molecular
mechanisms that initiate and propagate atherosclerosis[4,6].
I.1. Atherosclerosis
Atherosclerosis is a growing health problem leading to a significant increase in
mortality and morbidity worldwide. The disease is associated with lipid deposition in
the arterial vessel wall. The rupture of atherosclerotic plaques may cause death by
forming a sudden occlusive thrombus or embolic events leading to ischemia of the
heart or the brain. Therefore, the basic mechanism causing atherosclerosis are a major
research focus.
Atherosclerosis is considered a chronic inflammatory disease. Fibroinflammatory
lipid plaques are accepted as the characteristic atherosclerotic lesions. It is believed
that lesion progression in atherosclerosis is following a certain cascade of events.
Firstly, the subendothelial deposition of atherogenic lipoproteins facilitate the
activation of endothelial cells including adhesion molecule expression and
inflammation, which is characterized by the release of some signaling factors
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including chemokines[7.8]. Then monocytes are attracted to spots of activated
endothelial cells and transmigrate into the intimal space where these monocytes
differentiate into macrophages. These macrophages take up excess lipids and
transform into foam cells. Finally, foam cells die and liberate their contents, hence
attracting more macrophages to the growing plaque (Fig. 1).
Fig.1 Monocytes play a critical role in all stages of atherosclerosis. Following transmigration into
the subendothelial space monocytes transform into macrophages. Subsequently monocyte-derived
macrophages upregulate surface expression of scavenger receptors (SRs), which increases their
ability to take up modified LDL particles leading to foam cell formation.
In the early stages of atherosclerosis, serum lipids, especially oxidized lipoproteins,
are deposited underneath endothelial cells at arterial branch points/vessel bifurcations,
in part due to turbulent blood flow in these segments. After endothelial cells are
activated, the expression of adhesion molecules on the endothelial cells will increase.
Mediated by the chemokine receptors on their surface, monocytes are recruited to
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atherosclerotic lesions, adhere to the endothelial cells through the interactions with
adhesion molecules, and finally migrate into the subendothelial space. An et al has
shown that with genetic deletion or functional blockade of adhesion molecules, such
as ICAM-1, VCAM-1, CD18/β2 integrin, and P-selectin, the development of
atherosclerosis can be slowed down[9]. Combadière et al showed that the number of
circulating monocytes correlates positively with the atherosclerotic plaque size in
mice, and that functional alterations in monocyte/macrophages affects the
development of atherosclerosis[10].
In the later stages of atherosclerosis, when lesions are already established
macrophages continue to engulf extracellular oxidatively modified lipids by
receptor-mediated phagocytosis and pinocytosis. Zhou et al demonstrated that the
LDL receptor (LDLR) plays a key role in the process of modified lipoprotein
internalization by macrophages[11]. However, macrophage-derived foam cells are
found in atherosclerotic lesions even in patients with familial hypercholesterolemia
despite genetically impaired LDLR. Ashraf et al found a new class of receptors
(scavenger receptors, SRs) that bind to modified LDLs using acetylated LDL (acLDL)
as a model ligand[12]. Among these SRs, the type A scavenger receptor (SRA) and
CD36, a member of the type B family, have been extensively studied [13]. It is well
known that ApoE-deficient mice, which are widely used as an atherosclerosis model
spontaneously develop atherosclerotic lesions throughout the arterial tree [14,15].
Interestingly, Podrez et al showed that mice with CD36 and ApoE double deficiency
have reduced atherosclerotic lesions and greatly reduced uptake of oxLDL by
macrophages compared with their littermate controls[16]. Unlike the regulation of
LDLR expression, the expression of SRs is not downregulated by increased
intracellular levels of cholesterol. As a result, SR-mediated uptake of oxLDL leads to
the continuous absorption of lipoproteins and the accumulation of excess lipids by
macrophages[17]. The excess lipids are stored in lipid droplets in the cytoplasm,
creating a foamy appearance of the so called “foam cell” under the microscope and
are named as foam cells, a hallmark of atherosclerosis. Upon the uptake by
macrophages, lipoproteins are transported to the late endosome/lysosome, where
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cholesterol esters (CEs) are hydrolyzed into free cholesterol (FC) and fatty acids
(FAs)[18]. Because of the cytotoxicity of FC, the hydrolysis of CEs and the
reesterification of FC are very important in protecting macrophages and foam cells.
Similar to other cell types, FAs in macrophages bind to fatty acid-binding proteins
which are responsible for their intracellular function. Makowski et al have
demonstrated that, in macrophages, the absence of aP2, a fatty acid-binding protein
protect ApoE-knockout mice from atherosclerosis development[19]. Ghosh et al
recognized neutral cholesterol ester hydrolase (nCEH) as the rate-limiting enzyme in
the hydrolysis of CEs in macrophages[20]. In nCEH transgenic mice crossed into an
LDLR-null background the western diet induced atherosclerosis was significantly
reduced because of the enhancement of cholesterol efflux and reversed cholesterol
transport (RCT), which also resulted in increased cholesterol elimination as bile acids
in the feces[21]. These results demonstrate that macrophage-specific over expression
of nCEH is antiatherogenic and that this protein is potentially a novel target for the
treatment of atherosclerosis.
In conclusion, macrophage foam cells play a key role in all stages of atherosclerosis,
from the earliest lesions to complex plaques, and are a critical determinant of plaque
related complications. During the development of atherosclerotic plaques, monocytes
migrate into the arterial intima where they differentiate into macrophages and become
lipid-overloaded by uptake of excess lipoproteins. At the same time, cytotoxicity is
caused by the sustained increase of intracellular lipid concentrations. With the
accumulation of lipids in the macrophages, massive lipid droplets are formed leading
to the formation of foam cells. Better understanding of the mechanisms responsible
for plaques formation will be important in order to find a cure for atherosclerosis, one
of the major causes of death in western countries.
I.2. Oxidative stress (OS)
Oxidative stress (OS) is a condition that occurs when the steady balance between
prooxidants and antioxidants is lost, which will lead to damage to the organism.
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Prooxidants are defined as free radicals, atoms, or clusters of atoms with a single
unpaired electron[22]. Initially, oxidative stress has been described as an imbalance
between generation and elimination of reactive oxygen species (ROS) and reactive
nitrogen species (RNS), termed the redox system. These reactive species were first
thought to be “only” harmful to cells, but recent data suggests that the redox system
involving ROS is also involved in cell signaling i.e. kinase cascade activation, ion
transport, regulation of mitogen-activated protein (MAP), calcium mobilization, and
apoptosis[23]. The generation of oxidative stress was considered to be associated with
alterations in ROS, RNS, and nitric oxide (NO) production, whereby bioavailable NO
is decreased and ROS and RNS production are increased[24]. The signaling pathways
of the redox system are induced by inflammatory responses. Simultaneously,
mitochondrial metabolism generates high concentrations of free radicals. At the same
time ROS and RNS could also react with other substrates such as superoxide anion,
hydroxyl radical, and peroxynitrite. It was demonstrated that some physiological
defense signaling pathways can be offset by the production of ROS and RNS. Under
conditions of excessive production of ROS and RNS will damage fatty acids, proteins,
and DNA[25].
Recently, a research hotspot focusses on mechanism of production of oxidative stress
and the corresponding antioxidant signaling pathways, helping us to understand how
the internal environment is preserved from changes in the external environment. ROS
are a family of molecules including superoxide (O2-), hydroxyl (HO), hydrogen
peroxide (H2O2), nitric oxide (NO), and its derivatives like fatty acid peroxyl radical
(R-COO), peroxynitrite (ONOO-), and hypochlorous acid(HOCl)[26]. Via free
radicals, the production of one kind of ROS will also lead to the production of several
other kinds. The balance between the generation of ROS and NO composes the Redox
system. The reaction of O2- with NO also regulates the production of O2-. If the
production of ROS exceeds the endogenous antioxidant defenses, it will lead to the
damage of biological compounds, such as DNA, protein, carbohydrates, and lipids.
This situation was often referred as oxidative stress (Fig.2).
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Fig.2 ROS including O2-, HO, and NO can promote oxidative stress, which could cause damage to
biological compounds. The ROS system is counterbalanced by the NO system. Excessive
production of free radicals causes oxidative damage.
There is a plurality of latent enzymatic sources of ROS, including the mitochondrial
respiratory cycle, heme, arachidonic acid enzymes, cytochrome p450s, xanthine
oxidase, NO synthase.
I.3. Reactive oxygen species and vascular disease
Reactive oxygen species (ROS) are associated with the development of most
cardiovascular diseases. Vessel injury increases cytokines expression, which in turn
up regulates the production of ROS[27]. In contract, low levels of ROS participate in
preserving normal vascular function. However, excessive production of ROS leads to
monocyte adhesion, platelet aggregation, vascular smooth muscle cell (VSMC)
proliferation, migration and apoptosis. Vascular injury is usually initiated by
endothelial dysfunction and expression of adhesion molecules induced by cytokines
such as tumor necrosis factor-α (TNF-α) following ROS exposure. Then increased
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adhesion molecule expression attracts monocytes which transmigrate into the
subendothelial space, transform into macrophages and produce high amounts of ROS,
which may cause vascular leakage. ROS is also thought to participate in the VSMC
proliferation following vascular injury. In that respect, low doses of H2O2 mediate
most growth related signaling[28]. The intracellular production of H2O2 is thought to
be important, as ROS producing enzymes are found both in caveolae and focal
adhesions[29]. Moreover, high levels of ROS may cause apoptosis of vascular cells
following both inflammatory and mechanical injury.
I.4. Nitric oxide synthases (NOS)
Nitric oxide (NO) is known as a key secondary messenger molecule, which has
numerous molecular targets. NO's function is associated with many regulatory
signaling pathways such as vascular tone, neurotransmission, regulation of gene
transcription, mRNA translation and the production of post-translational
modifications of proteins[30,31]. It was suggested that one of the most important
functions of NO is its reaction with superoxide anion (O2-) to form peroxynitrite
(ONOO-), which may cause oxidative damage, nitration, and S-nitrosylation of
biomolecules including proteins, lipids, and DNA[32]. This nitrosative stress caused
by ONOO- has been related with DNA single-strand breaks, followed by
poly-ADP-ribose polymerase (PARP) activation[33].
In mammals, NO can be generated by three different isoforms of the enzyme NO
synthase (NOS). The isozymes are referred as neuronal nitric oxide synthases (nNOS
or NOS I), inducible nitric oxide synthases (iNOS or NOS II), and endothelial nitric
oxide synthases (eNOS or NOS III). All of the three isoforms of NOS use L-arginine
as the substrate, molecular oxygen and reduced nicotinamide-adenine-dinucleotide
phosphate (NADPH) as co-substrates. Flavin adenine dinucleotide (FAD), flavin
mononucleotide (FMN), and (6R-)5,6,7,8-tetrahydro-L-biopterin (BH4) are
recognized as the cofactors of all these three isozymes. The NO formed by NOS can
react with a number of target enzymes and proteins, such as soluble guanylyl cyclase
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which leads to the generation of cyclic GMP[34,35].
Interestingly, all three NOS isozymes have regulatory functions in the cardiovascular
system. Neuronal NOS is involved in the central regulation of blood pressure, and
nNOS-containing nerves participate in dilating certain vascular beds. In the function
of phosphodiesterase 5 inhibitors, the residual nNOS activity is also needed. Inducible
NOS is expressed in atherosclerotic plaques and is recognized as an important
mediator in septic shock triggered hypotension. Endothelial nitric oxide synthases has
the ability to dilate blood vessels, control the blood pressure, and has numerous
vasoprotective and anti-atherosclerotic effects.
I.4.1. Neuronal nitric oxide synthases (nNOS)
Neuronal nitric oxide synthases is normally expressed in neuronal tissues, epithelial
cells, mesanglial cells, skeletal muscle cells and cardiomyocytes, and involved in a
variety of physiological and pathological processes, including neurotransmission,
neurotoxicity, skeletal muscle contraction, body fluid homeostasis and cardiac
function[36]. Neuronal nitric oxide synthases contains a PDZ domain (PSD-95 discs
large/zona occludens-1 homology domain) and can directly react with the PDZ
domains of other proteins. These interactions determine the subcellular distribution
and the activity of the enzyme[37]. In neurotransmission, nNOS is associated with the
rough endoplasmic reticulum and the synaptic membrane, whereas in skeletal muscle,
nNOS localizes to the sarcolemma. It has also been shown that nNOS protein is
present in the cytosol[38]. Of the three isoforms of NOS, nNOS was the first enzyme
which was shown in an “uncoupled” form to produce superoxide instead of nitric
oxide[39]. In the presence of L-arginine, nNOS can generate nitric oxide and
superoxide, whereas in the absence of L-arginine, nNOS mediates superoxide
generation from the oxygenase domain. The proportion of these two radicals depends
on the concentration of BH4, which inhibits superoxide production from nNOS in a
dose dependent manner. However, independent of BH4, L-arginine may inhibit
superoxide production alone, suggesting that BH4 deficiency would not affect the
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production of superoxide by nNOS[40]. Besides superoxide, nNOS may also generate
hydrogen peroxide (H2O2) in the absence of L-arginine, in which BH4 has played a
critical role in regulating the generation of superoxide and hydrogen peroxide. The
enzymatic activity of nNOS is different compared to the other two NOS isoforms as it
has the ability to catalyze the uncoupled reaction. In this way, nNOS produces higher
amounts of superoxide than iNOS in the absence of substrate[41]. In both early and
advanced atherosclerotic lesions in humans nNOS is detectable in endothelial cells
and macrophages, whereas it is absent in normal vessels[42]. Our research suggests
that nNOS is expressed in the aorta of apoE ko and apoE/iNOS double knockout (dko)
mice[43,44]. As nNOS is induced in various vascular pathologies such as
atherosclerosis, vascular injury and hypertension, it not required for normal vessel
function. However, as it is constitutively expressed in the nervous system it might
normally influence the vascular system indirectly[45]. We have already shown that
genetic deletion of nNOS resulted in accelerated atherosclerosis in apoE ko mice,
suggesting that nNOS has the ability to protect from atherosclerosis development. We
also showed that nNOS improved the survival rate of atherosclerotic mice, as
apoE/nNOS dko mice had a 30% increased mortality compared to apoE ko controls.
Previously it has been speculated that nNOS localized towards to the lumen of the
vessel decreases adhesion of leukocyte and platelet while nNOS expressed in the
adventitia may inhibit smooth muscle cell proliferation[46]. Since in the absence of
the substrate L-arginine nNOS may be “uncoupled” the role of nNOS derived
superoxide and nitric oxide in the formation of atherosclerosis needs further
characterisation.
I.4.2. Inducible nitric oxide synthases (iNOS)
Inducible nitric oxide synthases is normally not constitutively expressed, but its
expression can be induced by cytokines and other agents in almost all the cell types.
With regards to the diseased cardiovascular system, iNOS can be expressed in many
nucleated cells such as vascular smooth muscle cells, cardiac myocytes and
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leukocytes. Unlike eNOS and nNOS which are usually regulated by intracellular
calcium levels, iNOS is independent of intracellular calcium levels since it contains
irreversibly bound calmodulin. Therefore, the induction of iNOS will result in
generation of massive amounts of nitric oxide[47]. iNOS’s expression is normally
regulated transcriptionally by cytokines such as tumor necrosis factor-α,
interleukin-1b, interleukin-2 and interferon gamma-g, or bacterial lipopolysaccharide
stimulation and post transcriptionally by LPS, IFN-γ, transforming growth factor-β
(TGR-β). Phosphorylation and the binding to caveolin-1 may also regulate the activity
of iNOS, which induces increased degradation of iNOS protein[48,49]. Interestingly,
uncoupling of iNOS may also be induced in the presence of high concentrations of
L-arginine, which suggests that iNOS is able to generate superoxide when L-arginine
is not rate limiting. In contrast to the fact that eNOS and nNOS generate superoxide
from their oxygenase domains, iNOS mediates the production of superoxide from its
reductase domain. Therefore iNOS was proposed to simultaneously generate nitric
oxide from L-arginine bound to its oxygenase domain, while generating superoxide
from its reductase domain[50]. The generation of superoxide and nitric oxide results
in iNOS mediated peroxynitrite generation, one of the strongest biological oxidants
which enhances the anti microbial activity of iNOS[51].
Under normal physiological conditions iNOS’s expression has important anti
microbial and anti tumor activities since the enzyme produces high cytotoxic
concentration of nitric oxide. However, under pathophysiologic conditions, the
production of high concentrations of nitric oxide and superoxide may become
detrimental. Therefore, the expression of iNOS by macrophages and smooth muscle
cells in atherosclerotic lesions has been taken as evidence for its detrimental role in
atherosclerosis, due to formation of peroxynitrite[52]. Our research before showed
that genetic deletion of iNOS resulted in a significant reduction of lesion formation in
apoE ko mice, suggesting a proatherogenic potential of iNOS[6]. iNOS’s expression
in atherosclerotic lesions has been detected in monocytes/macrophages, vascular
smooth muscle cells and lymphocytes. These various cell sources have the ability of
producing different amounts of iNOS and hence inducing iNOS’s expression in
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various compartments of the plaque. Moreover, these cellular sources could induce a
specific series of genes co-expressed with iNOS, which may also influence their
redox system and result in the formation of peroxynitrite by the production of both
nitric oxide and superoxide. Peroxynitrite can oxidize proteins and cause nitrosylation
of proteins which may influence protein function.
I.4.3. Endothelial nitric oxide synthase (eNOS)
eNOS is mainly expressed in endothelial cells and myocardial cell. Unlike iNOS,
eNOS is constitutively expressed. The activity of eNOS is regulated in multiple steps,
including transcription, post-translational modifications, substrate availability,
calmodulin, enzymatic cofactors such as FAD, FMN, protein–protein interactions
with Hsp-90 and caveolins[53]. Superoxide produced by uncoupled eNOS is believed
to result from BH4 deficiency rather than L-arginine deficiency[54]. As eNOS is
calcium dependent, activation by calcium could increase the generation of superoxide
by eNOS[55].
Endothelium derived nitric oxide has played an important role in the modulation of
vascular functions. Nitric oxide generated by eNOS acts as an endothelium derived
relaxing factor, and mediates important aspects of vascular functions, including
regulation of vascular tone and blood flow, the adhesion and aggregation of platelet
and leukocytes, the expression of surface adhesion molecules and the proliferation of
vascular smooth muscle cells in response to vascular injury[56].
A deficiency in the bioavailable vascular NO would in turn lead to dysfunction of
endothelium and the development of atherosclerosis. Uncoupling of eNOS has been
suggested the main reason leading to the reduced NO bioavailability. In many
vascular diseases uncoupling of eNOS is found[57,58].
It has been demonstrated that eNOS protects the vessel wall during injury.
Kawashima et al proved in a vascular remodeling model, that eNOS expression may
decrease intima proliferation, inflammation and the expression of adhesion molecules
such as VCAM-1[59]. At the same time genetic deletion of eNOS leads to the
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development of arteriosclerosis since our previous research showed that deletion of
eNOS results in acceleration of plaque formation in apoE ko mice[60]. Moreover, we
found that apoE/eNOS dko mice developed vascular complications like abdominal
aortic aneurysms, aortic dissections and distal coronary artery disease as observed in
human atherosclerosis[60]. Furthermore, apoE/eNOS dko mice were hypertensive and
showed impaired left ventricular function and cardiac hypertrophy, possibly a result of
chronic myocardial ischemia, resulting from coronary artery disease[60]. However, in
a model of eNOS over expressing apoE ko mice, an increase of atherosclerosis
development was observed possibly due to increased uncoupling of the enzyme[61].
I.5. Aims of the investigation
All the three NOS isoforms are expressed in the vascular wall during atherosclerosis
development. In the past we generated nNOS/apoE dko, eNOS/apoE dko and
iNOS/apoE dko mice to investigate the role of each NOS isoform in
atherosclerosis[6,43,60]. Genetic deletion of iNOS resulted in a significant reduction
of lesion formation which suggests that iNOS is proatherogenic[6]. However, the
detailed mechanism behind iNOS's proatherogenic action is unclear. In the research
presented here, we focus on characterisation of the underlying proatherogenic
mechanisms of iNOS.
A wealth of evidence suggests that the macrophage-derived foam cell plays a critical
role in all steps of atherosclerosis and during the development of plaque related
complications. One possible way to stop atherosclerosis could be to change the
behavior of these macrophages by changing their ability to migrate into and out of the
plaque. As iNOS has a proatheogenic character, we asked ourselves whether the
enzyme participates in the regulation of macrophage-derived foam cell migration?
Alleviation of the migratory arrest of macrophage-derived foam cells in the plaque
could help these trapped cells to leave the subendothelial space.
Therefore, we set out to test the hypothesis that oxLDL induced inhibition of
migration is iNOS-dependent.
Materials and Methods
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II. Materials and Methods
II.1. Materials
II.1.1. Mice
Mice were backcrossed for 10 generations to the C57BL/6J genetic background.
iNOS ko and apoE ko mice were obtained from The Jackson Laboratories. Offsprings
were crossed and the progenies were genotyped for iNOS and apoE by polymerase
chain reaction using a PCR protocol provided by the Jackson Laboratories. iNOS ko
and apoE ko animals were crossed to generate apoE/iNOS double knockout mice.
Mice were genotyped by PCR using protocols supplied by The Jackson Laboratories.
ApoE ko and apoE/iNOS dko animals were weaned at 21 days and fed a western-type
diet (42% of total calories from fat; 0.15% cholesterol; Harlan Teklad) for 10 weeks.
II.1.2. Instruments and Accessories
E-scan ESR spectroscope Bruker BioSpin GmbH
FACScan Calibur Becton Dickinson Bioscience
Fluorescence Microscope ZEISS
Mx3000P detector Stratagene
Spectrophotometer Pharmacia Biotech
pH meter InoLab
Incubator Heraeus
Centrifuge Eppendorf, Beckman
Water Bath Thermomix
1.5ml Tubes Eppendorf
15ml Tubes Cellstar
75cm2 culture flasks Corning, Cell star
6 wells Nunclon, Corning
Materials and Methods
18
25-G needle BD Bioscience
Trans-wells Corning
II.1.3. Reagents and antibodies
1400W dihydrochloride (1400W) Sigma
MCP-1 Sigma
Low-density lipoprotein Applichem
FITC-Annexin apoptosis kit BD Bioscience
FITC-phalloidin Sigma
APC-F4/80 eBioscience
Rat IgG 2a κ iso control apc eBioscience
siRNA transfection kit Santa Cruz
FITC-CD36 Abcam
Anti-FAK (phospho Y576+Y577) antibody Abcam
Secondary antibody to rabbit IgG Abcam
II.1.4. Cell Culture
RAW 264.7 cells CLS
RPMI 1640 medium Gibco
PBS Gibco
Fetal bovine serum Gibco
Penicillin/streptomycin Biochrom
L-glutamine Biochrom
DMEM Gibco
DAPI Vector
Methanol EMSURE
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II.1.5. Real time PCR
TriFast reagent peqGOLD
iScript cDNA synthesis kit Bio-Rad
EVAGreen PCR Master MIX Bio-Rad
Chloroform Sigma
Ethanol EMSURE
II.1.6. Krebs Hepes Buffer (KHB)
Calcium chloride dihydrate Sigma
Sodium chloride Sigma
Magnesium sulphate, heptahydrate Sigma
Potassium chloride Sigma
Sodium bicarbonate Sigma
Potassium dihydrogen phosphate Sigma
D(+)Glucose Sigma
Hepes Sigma
II.1.7. Electron Spin Resonance (ESR)
Iron (II) sulphate heptahydrate Sigma
DETC Alexis
CMH Noxygen
CP Noxygen
Deferoxamine mesylate salt Sigma
Pegulated Superoxide Dismutase (PEG-SOD) Sigma
Apocynin Sigma
Sodium Hydroxide Merck
Copper(II) sulfate Merck
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Protein Assay reagent Bio-Rad
II.2. Methods
II.2.1. Cell Culture
The murine macrophage cell line, RAW 264.7, was cultured and propagated in RPMI
1640 medium supplemented with 10% fetal bovine serum, 2mM L-glutamine and 1%
penicillin/streptomycin in a 75cm2 culture flasks at 37°C in humidified atmosphere of
5% CO2 and air.
II.2.2. Bone marrow cells (BMC)s preparation
For BMCs isolation, C57BL/6J mice (6 weeks old) were killed and the lower limbs
were removed. BMCs were flushed with Dulbecco's Modified Eagle Medium
(DMEM) from the medullary cavities of tibias and femurs using a 25-G needle. Then
cells were cultured in DMEM medium supplement with 10% fetal bovine serum , 1%
penicillin/streptomycin in a 75cm2 culture flasks (Corning) and incubated at 37°C in
an atmosphere containing 5% CO2.
II.2.3. In vitro migration assay (modified Boyden chamber
assay)
Cells were measured in a modified Boyden chamber migration assay using trans-well
inserts with a 5µm porous membrane (Corning). Cells were first pretreated with
nLDL, oxLDL, 1400W or siRNA. After that, cells were washed twice by PBS 50000
pretreated cells per group were added to 100µl medium and introduced into the upper
compartment of the trans-well. Into the lower compartment of the Boyden chamber
600µl medium containing MCP-1 in a concentration of 10ng/ml were added. The
chambers were incubated at 37°C in 5% CO2 for 18 hours. During this time the cells
in the upper compartment were allowed to migrate to the lower side of the membrane.
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(Fig.3) The membrane was harvested and cells on the lower side of the membrane
were fixed with methanol for 8 minutes and then these cells were stained with 1 drop
of DAPI. At last, the lower side of the membrane was photographed under a
fluorescence microscopy. The number of the cells on each picture was counted by
image Pro-Plus software.
Fig.3 Boyden chamber consists of two compartments, 50,000 pretreated cells in 100µl medium
were added to the upper compartment, 600µl medium with MCP-1 in a concentration of 10ng/ml
was added to the lower compartment. Cells in the upper wells were allowed to migrate towards
the lower side of the membrane.
II.2.4. Flow cytometry assays
To quantify apoptosis in oxLDL and 1400W treated cells, cells were first washed
twice by PBS. Then 105 cells were suspend with 1×Binding buffer incubated with
FITC–annexin V and propidium Iodide (PI) at room temperature for 15 minutes in the
dark, and then analyzed.
To measure polymerized actin (F-actin), RAW 264.7 cells were preincubated with
nLDL, oxLDL or oxLDL plus 1400W at 37°C in 5% CO2 for 24 hours. After
Materials and Methods
22
incubation, cells were washed twice by PBS, and 105 cells were suspended with FACS
buffer (PBS with 1% BSA) then fixed with 4% paraformaldehyde for 8 minutes. After
washed twice again cells were treated with 0.1% Triton and then stained with
FITC-conjugated phalloidin at room temperature for 60 minutes in the dark.
Following this the fluorescence intensity was quantified.
To measure phosophorylated focal adhesion kinase (p-FAK), RAW 264.7 cells were
preincubated with nLDL, oxLDL or oxLDL plus 1400W at 37°C in 5% CO2 for 24
hours. After incubation, cells were washed twice with PBS, and 105 cells were
suspended with FACS buffer (PBS with 1% BSA) then fixed with 4%
paraformaldehyde for 8 minutes. After washed twice again cells were treated with
0.1% Triton and then incubated with anti-p-FAK antibody at room temperature for 40
minutes in the dark. Then cells were washed twice again and incubated with Alexa
Fluor® 488 conjugated secondary antibody at room temperature for 40 minutes in the
dark. After washed twice the fluorescence intensity was quantified.
To measure F4/80 positive bone marrow cells, 105 cells were suspend with FACS
buffer, then incubated with APC–F4/80 antibody at room temperature for 60 minutes
in the dark. After that the fluorescence intensity was quantified.
All flow cytometry were tested using a BD FACScan (Calibur). Data were analyzed
by Flowjo 7.6.1.
II.2.5. Real time PCR
Total RNA was extracted from cells using TriFast reagent (peqGOLD). After the
medium was removed, 1ml TriFast was directly added to cells in a 6 well chamber.
The solution in the 6 wells was passed several times by pipette. For dissociation of the
nucleoprotein complexes the samples were kept for 5 minutes at room temperature.
After that the solution was transfered into tubes and 0.2 ml chloroform was added.
The tubes were vortexed, then kept on ice for 10 minutes. Tubes were centrifugate for
5 minutes, 4°C, at 12,000 g. The mixture then separates into the lower red
(phenol-chloroform phase), the interphase and the colorless upper aqueous phase.
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RNA is located exclusively in the aqueous phase whereas DNA and proteins move
into the interphase and lower phenol phase. Following the transfer of the aqueous
phase to a fresh tube RNA was precipitated with 0.5ml of isopropanol per tube. Each
samples was incubated on ice for 10 minutes and centrifugated for 10 minutes at 4°C
at 12,000g. The RNA pellet forms a gel like precipitate on the bottom and the side of
the tube. The supernatant was carefully removed and we then washed RNA pellet
twice with 75% ethanol by vortexing. Subsequently the samples were centrifugated
for 10 minutes at 4°C at 12,000g. Excess ethanol was removed and the RNA was
dried at room temperature. At last RNA was resuspended in 50µl RNase-free water
and heated in water bath at 55-60°C. The concentration and the purity of RNA was
tested by spectrophotometer (wave length 260/280 nm).
cDNA was synthesized from 1µg of total RNA using iScript cDNA synthesis kit
following the instructions of the company. Gene expression was analyzed by
quantitative RT-PCR using the EVA Green PCR Master MIX with the Mx3000P
detection system and relative quantification software. The expression levels of each
gene were determined using the comparative Ct method and normalized to β-actin, as
internal control. The primers are listed in Table 1.
Table 1 Primers used for real-time PCR analysis
Gene
Primer sequence
Forward Reverse
iNOS 5′-GTTTCTGGCAGCAGCGGCTC-3′ 5′-GCTCCTCGCTCAAGTTCAGC-3′
β-actin 5′-CGTGGGCCGCCCTAGGCACCAGGG-3′ 5′-GGGAGGAAGAGGATGCGGCAGTGG-3′
t-FAK 5′-GAGAATCCAGCTTTGGCTGTT-3′ 5′-GGCTTCTTGAAGGAACTTCT-3′
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II.2.6. Silencing iNOS expression in RAW 264.7 cells employing
siRNA
RAW 264.7 cells were seeded in 6-wells for 18h. siRNA was introduced into RAW
264.7 cells by using siRNA transfection reagent following the manufacture
instructions.
II.2.7. Electron spin resonance (ESR)
Most usually used methods for measuring the free radicals employ reduction of
cytochrome C and chemiluminescence. However because of side reactions of
cytochrome C and chemiluminescence, these methods are usually not exact. In
contrast, electron spin resonance (ESR), the method which we employed provides
specific and direct measurement of free radicals.
The detection by ESR spectroscopy relies on the detection of magnetic properties of
unpaired electrons and their molecular environment. Electrons possess a property
which was called spin. The unpaired electrons exists in the magnetic field two
orientations, parallel and antiparallel. Electrons in the antiparallel state possess higher
energy than electrons in the parallel state. The total energy between the two spin states
is detected by resonance. Only free radicals which contain unpaired electrons produce
an ESR signal. An external magnetic field of a specific strength is applied for the
transition to occur such that the difference in energy levels is matched by a
microwave frequency.
In biological samples free radicals such like nitric oxide, superoxide and peroxynitrite
are found in very low concentrations and are too short lived to be directly detected.
This problem can be solved by the addition of exogenous spin traps which can react
with free radicals to form secondary ESR detectable radicals in a stable state.
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II.2.8.Krebs Hepes Buffer (KHB)
KHB with the following composition, prepared in Milli Q water, was used for the
experiments: Sodium chloride 99mM, Potassium chloride 4.69mM, Calcium chloride
2.5mM, Magnesium sulphate 1.20mM, Sodium bicarbonate 25mM, Potassium
dihydrogen phosphate 1.03mM, D (+) Glucose 5.6mM, Sodium Hepes 20mM. These
reagents were dissolved in 500ml of MilliQ water. The pH was adjusted to 7.4. The
pH was checked every day before use and the buffer was filtered using a 0.22µm filter
(Millex).
II.2.9. Measurement of NO Production by ESR
NO production of RAW 264.7 was measured in an organ bath using colloid iron (II)
diethyldithiocarbamate (Fe(DETC)2) as a spin trap and ESR detection. The method
was adapted for detection of baseline NO production in RAW 264.7 cells. Briefly,
cells were washed twice by PBS and then suspended at 4°C in chilled Krebs-Hepes
Buffer (KHB). A mix of 1000µl of FeSO4 and DETC solutions were bubbled with N2
at least 20 min, and 1000µl were added to each dish (total amount 4ml). The cells' NO
production was trapped with Fe-(DETC)2 for 1 hour in 37°C KHB. KHB with
Fe(DETC)2 was removed from the dish by scraping cell, and 100µl cell suspension
were frozen in liquid N2 and tested. Following ESR measurement to the protein
concentration of the samples were quantified with a protein assay reagent (Bio-Rad)
and used to normalize the ESR signal intensity. The general settings of ESR were:
microwave frequency 9.431GHz, modulation frequency 86 kHz, center field, 3280G;
modulation amplitude 6G; field sweep 80G; microwave power 40mW; scan time
120s.
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II.2.10. Measurement of reactive oxygen species (ROS) and
peroxynitrite by ESR
The generation of ROS by RAW 264.7 cells was measured by ESR detection (e-scan
ESR spectrometer). A stock solution of spin probe (10mm, 2.3mg for 1ml KHB) in
buffer containing 25µM Defferoxamine and 5µM DETC and a suspension of cells in
the concentration of 400,000/ml native or 800,000/ml cultured cells were prepared.
Cells were washed twice by PBS and then suspended in KHB containing 25µM DF
and 5µM DETC at 4°C. Forty-five µL of cell suspension and 2.5µL of spin probe
solution were mixed. ROS production was assessed by pre incubating cells with
PEG-SOD (50U/ml) parallel to 1-hydroxy-3-methoxycarbonyl-2,2,5,5-
-tetramethylpyrrolidine (CMH) for 30min at 37°C. The reaction was stopped by
putting the sample on ice.
Uric acid was used as a scavenger for peroxynitrite[62]. Peroxynitrite formation of
RAW 264.7 cells was calculated as the difference of ROS production between each
group before and following uric acid treatment.
The intensity of the ESR signal was normalized to the sample’s protein content. ESR
settings: Center field 1.9901g, microwave power 1mW, modulation amplitude 5G,
sweep time 10s, field sweep 60G, gain 1×103.
II.2.11. Statistical analyses
We performed student'T test and a P-value of less than 0.05 was considered
significant. Data are expressed as mean±SD. The analyses were formed using SPSS
Statistics 17.0.
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III. Results
III.1. Migration assay
III.1.1. Migration of RAW 264.7 cells
RAW 264.7 cells were divided into four groups: 1. unstimulated cells; 2. cells
incubated with non-oxidized low density lipoprotein (nLDL); 3. cells incubated with
oxidized low density lipoprotein (oxLDL); 4. cells incubated with oxLDL plus 1400W
(50µM), an iNOS inhibitor. All groups were incubated at 37°C for 24 hours.
Following this, cells were introduced into a modified Boyden chamber in order to
quantify cell migration in response to an MCP-1 gradient. Cells which migrated
towards the lower side of the membrane were counted using a fluorescence
microscope. Four random fields in each filter were examined. Each experiment was
performed in five times, and migration was expressed as the mean±S.D. of total cells
counted per field.
Migration of oxLDL treated cells was significantly reduced compared to unstimulated
cells (228.3±48.9 versus 376.5±28.7, p<0.05), while nLDL treated cells showed no
difference compared to unstimulated cells (340.9±43.5 versus 376.5±28.7, p>0.05).
Interestingly, the migratory arrest in response to oxLDL treatment was reversed by
coincubation with 1400W (228.3±48.9 versus 358.9±55.1, p<0.05) (Fig.4 and 5).
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Fig.4 Migrated RAW 264.7 cells on the lower side of the membrane were stained with DAPI and
counted under a fluorescence microscope using a ×10 objective. Representative pictures of each
treatment group.
Results
30
ba
se
lin
e
nL
D
L
ox
LD
L
ox
LD
L+
14
00
W
0
50
100
150 *
*
c
e
ll
 m
ig
ra
ti
o
n
 (
%
 o
f 
b
a
s
e
li
n
e
)
Fig.5Migrated cells of each goup. Significance was determined by T-test. (*, P<0.05, n=5)
To detect the effect of NO on cell migration we used SIN-1, an NO donor to stimulate
RAW 264.7 cells and measured cell migration employing the migration assay as
described above.
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Fig.6 RAW 264.7 cells were pretreated with SIN-1(0.3mM). Migrated cells quantified as
described above.(*, P<0.05, n=4)
As shown in Fig.6, when cells were stimulated with SIN-1, the migration was
significantly inhibited. We then used Trolox, a strong antioxidant to test whether an
antioxidant known to reduce the production of lipid peroxides could reverse the
inhibition of cell migration caused by oxLDL. As shown in Fig.7, the inhibition
induced by oxLDL was reversed by Trolox.
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Fig.7 RAW 264.7 cells were pretreated with oxLDL or pretreated with oxLDL plus Trolox
(0.2mM). Migrated cells quantified as described above. (*, P<0.05, n=6)
III.1.2. Apoptosis
To exclude the possibility that the inhibitory effect of oxLDL was due to induction of
raw cell apoptosis, we analyzed Annexin V and propidium lodide staining of the raw
264.7 cells by flow cytometry.
In the flow cytometry scatter plot (Fig.8), the cells in the lower left quadrant (FITC
negative, PI negative) were defined as live cells, in the lower right quadrant (FITC
positive, PI negative), cells were defined as apoptotic cells and in the upper right
quadrant (FITC positive, PI positive), cells were defined as dead cells.
All the measurement were repeated for five times for each group. There were no
significant differences between the percentage of live cells, apoptotic cells and dead
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cells in each group: live cells, baseline (80.7±3.67), nLDL (78.8±2.65), oxLDL
(79.5±1.97), oxLDL+1400W (79.2±2.19); apoptotic cells, baseline (0.60±0.48), nLDL
(0.73±0.29), oxLDL (0.534±0.32), oxLDL+1400W(0.58±0.26); dead cells, baseline
(10±6.63), nLDL (14.7±2.99), oxLDL(13.3±2.54), oxLDL+1400W (13.7±1.64).
Fig.8 RAW 264.7 cells were stained with annexin V and PI and subjected to analysis by flow
cytometry. (n=5)
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III.1.3. Migration of siRNA treated RAW 264.7 cells
To confirm the importance of iNOS in oxLDL induced inhibition of macrophage
migration, we treated RAW 264.7 cells with small inhibitory RNA (siRNA) to silence
iNOS gene expression and quantified cell migration in the same way as described
before. These experiments revealed that the inhibition of migration by oxLDL was
totally reversible by the treatment of the cells with iNOS-siRNA (Fig.9).
Fig.9 RAW 264.7 cells pretreated with control RNA or siRNA were exposed to nLDL and oxLDL
and migrated cells quantified as described above.
In the control RNA (nonsense RNA/no inhibition of iNOS expression) treated groups
oxLDL (“goup 3”) significantly reduced migration compared with “group 1” cells
(188.7±58.1 versus 390.8±42.3, p<0.05) or nLDL treated “group 2” cells (385.8±31.9,
p<0.05). In contrast, siRNA treatment abrogated the migratory arrest by oxLDL such
that no significant difference in migration was seen between “group 1” (397.6±11.5),
nLDL “group 2” (390.2±52.3) compared to oxLDL “group 3” (395.6±23.5) cells
(p>0.05). (Fig.10)
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Fig.10Migrated cells of each goup expressed as percent of baseline migration. (*, P<0.05, n=5)
III.1.4. Bone marrow derived macrophage migration
Here we used bone marrow derived macrophages of apoE/iNOS double knockout and
apoE knockout mice to test differences in cell migration in a model of chronic iNOS
deletion. (Fig.11)
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Fig.11 Bone marrow derived macrophages of apoE ko mice or apoE/iNOS dko mice were exposed
to oxLDL, introduced into a Boydem chamber and migrated cells were quantified as described
above. (*, P<0.05, n=5)
To verify that bone marrow derived cells were indeed macrophages, we stained the
cells for F4/80, a marker for macrophages and analyzed them by flow cytometry.
(Fig.12)
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Fig.12 Bone marrow derived macrophages were stained with fluorochrome labeled anti-F4/80 and
anti-CD36 antibodies. Fluorescence intensity was analyzed by flow cytometry.
Under baseline conditions apoE/iNOS double knockout macrophages migrated to the
same extent as apoE knockout macrophages. In contrast, in the presence of oxLDL,
apoE knockout macrophage migration was significantly inhibited, while apoE/iNOS
double knockout macrophage migration was not inhibited. This finding in this chronic
iNOS deletion model further supported the hypothesis that oxLDL-induced inhibition
of macrophage migration in vitro is partially dependent on iNOS.
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III.2. OxLDL regulates expression of iNOS in RAW 264.7
cells
To test whether oxLDL increases the iNOS expression in RAW 264.7 cells we used
quantitative RT-PCR and quantified iNOS mRNA levels. RAW 264.7 cells were
divided into five groups: Unstimulated cells, cells treated with nLDL, cells treated
with oxLDL, cells treated with oxLDL plus 1400W (50µM) and cells treated with
LPS (1µg/ml) as a positive control. The iNOS mRNA expression of oxLDL treated
cells was significantly higher compared to unstimulated cells and nLDL treated cells
(p<0.05) (Fig.13).
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Fig.13 The iNOS expression of RAW 264.7 cells of each group was tested by Real time PCR
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using the comparative CT method. (*, P<0.05, n= 3)
III.3. iNOS inhibition with 1400W was associated with a
reduction in NO and peroxynitrite formation and an
increase in superoxide generation
Pharmacologic iNOS inhibition with 1400W was associated with a significant
reduction in NO and peroxynitrite formation and a significant increase in superoxide
generation. (Fig.14, 15, 16)
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Fig.14 The intracellular NO production was measured by ESR. (*, P<0.05, n=5)
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Fig.15 The intracellular ROS was measured by ESR. (*, P<0.05, n=5)
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Fig.16 The intracellular peroxynitrite was measured by ESR. (*, P<0.05, n=6)
The NO and peroxynitrite production was significantly increased in oxLDL treated
cells. Moreover, this increase could be abrogated by pharmacologic iNOS inhibition
with 1400W. ROS production was significantly decreased by oxLDL treatment, which
could also be reversed by 1400W.
III.4. The inhibition of migration was associated with actin
polymerization
As cell spreading requires actin polymerization to form lamellipodia[63], the
inhibition of migration is usually associated with actin polymerization, a marker for
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cell spreading and migratory arrest. We therefore examined the effect of oxLDL on
actin polymerization in macrophages. RAW 264.7 cells were divided into four gourps:
unstimulated cells, treated with nLDL, oxLDL or oxLDL plus 1400W (50µM) and
then stained with fluorescein-conjugated phalloidin to detect polymerized actin. Each
experiment was performed five times, and fluorescence intensity was detected by flow
cytometry. (Fig.17).
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Fig.17 RAW 264.7 cells were stained with FITC-phalloidin and subjected to analysis by flow
cytometry. (*, P<0.05, n=5)
Flow cytometric analysis showed that the amount of polymerized actin did not differ
between baseline and nLDL treatment. However, oxLDL treatment increased
phalloidin staining, an effect which was abrogated by pharmacologic iNOS inhibition
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with 1400W.
III.5. Inhibition of migration was associated with increased
phosphorylation of focal adhesion kinase
First, we used real time PCR to see whether the RNA content of total focal adhesion
kinase (t-FAK) differed between the groups. As shown in Fig.18, there is no
difference of t-FAK expression in each group.
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Fig.18 The t-FAK expression of RAW 264.7 cells of each group was test by Real time PCR using
comparative CT method. (*, P<0.05, n=3)
Then we used FACS to analyze the expression of phosphorylated focal adhesion
kinase (p-FAK). As shown in Fig.19, expression of p-FAK was significantly increased
in the oxLDL treated group, an effect that was completely reversed by 1400W.
Results
44
ba
se
lin
e
nL
D
L
ox
LD
L
ox
LD
L+
14
00
W
0
5
10
15
*
*
F
lu
o
re
s
c
e
n
c
e
 i
n
te
n
s
it
y
 o
f 
p
-F
A
K
Fig.19 RAW 264.7 cells were stained with p-FAK and subjected to analysis by flow cytometry. (*,
P<0.05, n=3)
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IV. Discussion
With substantial advances in our understanding of the molecular and cellular biology
of atherosclerosis progression and regression, macrophage derived foam cells have
been seen as key player in all stages of atherosclerosis, from the earliest discernable
lesions to complex plaques, and are a key determinant of related cardiovascular
complication.[64].
Previous research regarding atherosclerotic plaque progression and regression were
focused on the development of atherosclerotic lesions and the important role of
macrophages in plaque development and macrophage emigration to regional lymph
nodes in lesion regression[64–68]. The formation of macrophage-derived foam cells
is central to atherosclerotic plaque development[7]. The molecular mechanism of
foam cell formation is generally believed to consist of the following steps: first the
endothelium is activated following the accumulation of modified lipoproteins in the
subendothelial space; monocytes are attracted by chemoattractants and migrate into
the intima; monocytes differentiate into macrophages and take up modified
lipoproteins; excess lipids accumulate in macrophages forming lipid-laden foam cells,
foam cells die and release their contents, thus attracting more macrophages[69]. It is
known that oxidized low density lipoproteins (oxLDL) inhibit macrophage migration
and trap cholesterol laden foam cells in arteriosclerotic plaques. But the mechanisms
involved in macrophage-derived foam cell trapping in the inflamed atherosclerotic
neointima are incompletely understood, yet represent a novel target for potential
therapeutic interventions[70]. Therefore, if we can inhibit the signals which cause the
migratory arrest and reverse the ability of macrophage-derived foam cells to migrate
again, it may be possible to reverse the development of plaques and potentially
atherosclerosis.
As we know, unlike the other two isoforms of NOS, eNOS and nNOS which are
constitutively expressed, iNOS is expressed only when induced by external stimuli.
iNOS is not found in healthy vessels, however, in response to stimulation with
inflammatory cytokines or low PH (PH7.0) in the microenvironment of inflammatory
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lesions, iNOS is expressed by macrophages and vascular smooth muscle cells[71,72].
Aside from its transcriptional regulation, multiple post-translational modifications of
iNOS have been identified that may allow complex regulations of the catalytic
activity of iNOS[48,73-76]. iNOS protein also produces high amounts of nitric oxide
(NO) which is highly reactive with other free radicals. NO reacts with superoxide (O2-)
to form peroxynitrite (ONOO-), which in turn leads to protein nitration, DNA damage
and PARP activation. Peroxynitrite reacts with other molecules to form a variety of
oxgen- and nitrogen free radicals i.e. Nitrogen dioxide (·NO2), peroxynitrous acid
(·ONOOH) and hydroxyl radical (·OH)[77,78]. While eNOS and nNOS generate
superoxide from their oxygenase domains, iNOS may catalyse the production of
superoxide from its reductase domain. Therefore, iNOS was proposed to
simultaneously generate nitric oxide from L-arginine bound to its oxygenase domain,
while generating superoxide from its reductase domain[50].
Under physiological conditions, iNOS is unlikely to have a functional role in the
cardiovascular system due to its low expression level. However, under pathologic
conditions iNOS expression is thought to have important anti-microbial and
anti-tumor activities since it is able to generate high cytotoxic concentration of nitric
oxide. A large number of reports are available which provide evidence for the
expression of iNOS under pathophysiological conditions, both in humans as well as in
animal models. Recent research revealed that iNOS had both positive and negative
effects on atherosclerosis. As described before, vascular expression of iNOS could
protect from developing transplant arteriosclerosis and vein graft arteriosclerosis by
inhibiting vascular smooth muscle cell proliferation and neointimal
hyperplasia[79,80,81]. On the other hand iNOS deletion could act as a negative
regulator of leukocyte trafficking in the microcirculation, decrease smooth muscle cell
proliferation and prevent neointima formation following balloon angioplasty, protect
aortic allografts from developing allograft arteriosclerosis, improve cardiac reserve
following myocardial infarction, and partially protect against acute cardiac
mechanical dysfunction mediated by pro-inflammatory cytokines[82].
The seemingly opposing effects of iNOS under different pathological conditions may
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be due to the differences in the cellular compartment of iNOS expression. However,
iNOS expression relevant to atherosclerosis development was detected in vascular
smooth muscle cells, mononuclear cells and lymphocytes. These various cellular
sources are capable of generating different amounts of iNOS and subsequently target
iNOS expression to various compartments of the plaque. The expression of iNOS by
macrophages and smooth muscle cells in atherosclerotic lesions has been taken as
evidence for its detrimental role in atherosclerosis, due to the formation of
peroxynitrite[52].
Our previously research has shown that iNOS increases plaque development and
plasma lipid peroxides in atherosclerotic apoE knockout mice[6,44]. Furthermore, our
past results have shown that iNOS simultaneously increases NO and O2- production
and nitrosative stress in the atherosclerotic plaques. Therefore, iNOS may directly
increase proatherosclerotic oxidative stress[83].
Our results show that iNOS is involved in the process of inhibition of foam cell
migration. Here, we present pharmacologic and genetic evidence that oxLDL induced
iNOS expression inhibits macrophage-derived foam cell migration. Therefore,
strategies which reduce iNOS expression in the plaque potentially reverse migratory
arrest of macrophage-derived foam cells and reverse plaque formation. In our
modified Boyden chamber test, the migration of macrophages was significant reduced
by oxLDL treatment. Using 1400W, a pharmacologic inhibitor, migration was fully
restored. Furthermore, iNOS siRNA mediated silencing of iNOS transcription
additionally restored migration in oxLDL treated macrophages. Since our observation
of iNOS’s pro-atherosclerotic action was made in apoE/iNOS dko mice, we isolated
bone marrow cells from these mice, and subjected them to migration. In this genetic
model of chronic iNOS deletion, lake of iNOS led to a resistance towards oxLDL
mediated cell arrest as apoE/iNOS dko macrophages migrated normally following
uptake of oxLDL. As we already described above, oxLDL is thought to be one main
reason in vivo which promotes endothelia dysfunction and the formation of foam cells.
Progress of atherosclerosis is tightly associated with the accumulation of
macrophage-derived foam cells induced by oxLDL in plaques. However, the
Discussion
49
particular mechanism involved in the regulation of macrophage migration and the
signaling pathway involved are still unclear. Here, on the basis of our previous
research on iNOS, we have proved that iNOS modulates the migratory ability of
macrophage-derived foam cells. iNOS inhibition could be a target to revers deposition
of macrophage-derived foam cells in atherosclerosis.
We have also showed that oxLDL-mediated signals led to enhancement of actin
polymerization and phosphorylated focal adhesion kinase (p-FAK), which are
associated with iNOS expression. As we know, actin-based motility, driven by the
assembly of actin filaments may be one important way to direct movements of cells.
Actin-based motility describes a variety of cellular processes through which living
cells change shape in response to environmental signals, or extend protrusions like
lamellipodia and filopodia, or wrap around a particle in a phagocytic cup. Progress in
understanding the mechanism by which actin polymerization generates movement
resulted from advances in different fields[63]. The cell migration process consists of
actin polymerization driven lamellipodia extension, disruption of existing focal
contacts, and formation of new focal contacts[84]. Mechanistically, this inhibition was
associated with enhancement of focal adhesion kinase (FAK) phosphorylation and
actin polymerization[70]. Since the signaling pathway required for actin
polymerization includes activation of FAK[85], it has been suggested that the
sustained activation of FAK may lead to inhibition of migration[86]. Moreover, the
hyperphosphorylation of FAK in cells is associated with the inhibition of
migration[87].
Interestingly, when we inhibit iNOS expression, actin polymerization and p-FAK
were also significantly reduced. That is to say, the iNOS expression mediated by
oxLDL may lead to an increase of actin polymerization and FAK phosphorylation.
For a better understanding of the underlying pathomechanism we performed a
detailed analysis of oxidative stress using Electron Spin Resonance (ESR)
spectroscopy measurement of reactive oxygen species (ROS), NO and peroxynitrite
production. As we described before, oxidative stress caused by ROS, NO and
peroxynitrite may lead to vascular injury. Moreover, in the atherosclerosis lesions
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oxidative stress is increased compared to healthy vascular tissue, suggesting that
oxidative stress is one important mediator or direct factor to causing the trapping of
macrophages in the intima. Our studies revealed that oxLDL significantly increases
macrophage-derived foam cell production of NO in an iNOS dependent manner.
Interestingly, ROS production of the macrophage-derived foam cells following
oxLDL treated is significantly reduced compared to unstimulated cells. We conclude
that this may be the result of excess NO which reacts with ROS to form peroxynitrite,
one of the strongest known oxidants in biological samples. We speculate that
increased peroxynitrite formation leads to increased production of lipid peroxides
which are strong inducers of protein tyrosine phosphatases (PTPs) by their
oxidation[88]. Today, there is a wealth of evidence supporting peroxynitrite mediated
lipid peroxide oxidation[89]. With regards to this, we found increased levels of
malondialdehyde (MDA) in plasma of apoE/iNOS dko mice[6]. In this way, oxidative
inactivation of PTP would result in sustained phosphorylation of FAK and increased
actin polymerization. The expression of iNOS signaling will then cause the inhibition
of migration.
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Fig.20Model depicting mechanisms of macrophage migratory arrest.
Park et al showed that oxLDL-CD36 interactions in macrophages led to NADPH
oxidase-mediated generation of intracelluar ROS, which in turn led to oxidative
inactivation of SHP-2 and migration[70]. Unpublished data from our lab suggests that
THP-1 cells used in the Park publication do not produce iNOS following oxLDL
treatment. Furthermore, they did not investigate NO production used in their murine
macrophage preparations. In our experiments iNOS induction led to a decrease in
superoxide formation, most likely because superoxide was scavenged by NO to form
peroxynitrite. Given the above presented references which showed that peroxynitrite
is capable of generating lipid peroxides it is interesting that recent data found that
lipid peroxides are much more effective in PTP oxidation compared to ROS
(nanomolar range for lipid peroxides vs. micromolar range for ROS) [88]. Our results
show that Trolox (VitE), an antioxidant known to reduce lipid peroxidation, can
reverse the inhibition of migration caused by oxLDL. Thus, we hypothesise that iNOS
driven peroxynitrite mediated formation of lipid peroxides may drive a much stronger
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signal which can inhibit migration in macrophages.
In conclusion, our data identified a novel iNOS depending pathway modulating
macrophage-derived foam cell migration. This finding may explain some of the
proatherogenic functions of iNOS in our model and suggests that iNOS might be a
target gene to reverse atherosclerosis.
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Summary
Macrophage-derived foam cells play a critical role in all stages of atherosclerosis,
from the earliest discernable lesions to complex plaques. oxLDL is thought to be a
main trigger for endothelial release of pro-inflammatory cytokines, subsequently
causing transmigration of the monocytes into the vessel wall. Moreover, formation of
macrophage-derived foam cells is mainly induced by oxLDL. Deposition of
macrophage-derived foam cells in the lesions is induced by oxLDL uptake, as this
uptake causes migratory arrest of the cells. Therefore, reversion of migratory arrest of
macrophage-derived foam cells might enable these cells to leave the plaques resulting
in reduction of plaque sizes.
Our results show that iNOS participates in the mechanisms of oxLDL induced
inhibition of macrophage-derived foam cell migration. Inhibition of iNOS expression
completely reversed oxLDL mediated migratory arrest of macrophage-derived foam
cells. Inhibition of iNOS was associated with enhanced phosphorylation of focal
adhesion kinase (FAK) and subseqent actin polymerization. Furthermore, the p-FAK
triggered increase in actin polymerization is dependent on iNOS mediated increased
oxidative stress. Our results suggest that iNOS may be an interesting target gene to
reverse the process of atherosclerosis.
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Zusammenfassung
Die aus den Makrophagen entstehenden Schaumzellen spielen eine wichtige Rolle in
allen Stadien der Atherosklerose – von den frühesten erkennbaren Läsionen bis hin
zur Entstehung komplexer atherosklerotischer Plaques. Man nimmt an, dass oxLDL
einer der Hauptgründe für die Freisetzung von Entzündungsfaktoren von
Endothelzellen ist, die Monozyten zu einer Transmigration in die Gefässwand
verleiten. Außerdem wird die Entstehung von Schaumzellen aus Makrophagen
hauptsächlich durch oxLDL verursacht. Man weiß, dass die Ablagerungen von
Schaumzellen die Hauptbestandteile der atherosklerotischen Läsion darstellen, was
vermuten lässt, dass der Verlust der Migrationsfähigkeit der Schaumzellen einen
wesentlichen Anteil in der Entstehung von Plaques hat. Die Wiedererlangung der
Migrationsfähigkeit der Zellen könnte dazu führen, dass Schaumzellen die
Gefässwand verlassen können und somit eine Regression der Plaquebildung erreicht
werden kann.
Unsere Ergebnisse zeigen, dass iNOS in dem Mechanismus des Migrationsarrestes
eingebunden ist. Durch die Hemmung der iNOS-Expression konnte der
migrationshemmende Effekt des oxLDLs signifikant reduziert werden. In unseren
Experimenten förderte die oxLDL induzierte iNOS-Expression die p-FAK Bildung
und Polymerisation von Aktinfilamenten, was den Effekt dieses Gens auf die
Migrationshemmung des oxLDLs erklärt.
Die Hemmung der iNOS vermindert oxidativen Stress, was die von uns gezeigte
proatherogene Funktion von iNOS erklärt. Unsere Ergebnisse identifizieren iNOS als
vielversprechendes Zielgen zur Bekämpfung der Arteriosklerose. Unsere Studien
weisen in die Richtung eines bislang unbekannten Makrophagen-Signalwegs,
ausgelöst durch oxLDL und gefödert durch Induktion der iNOS Expression. Sie
bieten eine Erklärung für den durch oxLDL ausgelösten Migrationsarrest von
Makrophagen in atherosklerotischen Läsionen, erklären eine mögliche Rolle von
Zusammenfassung
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iNOS als Enzym mit proatherosklerotischer Funktion und zeigen neue Wege der
Mobilisation und Emigration von Schaumzellen aus atherosklerotischen Plaques.
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Abbreviation
Apo E:
BH4:
CEs:
CMH:
CP:
DETC:
ESR:
FAD:
FAs:
FC:
FMN:
KHB:
LDL:
MAP:
MCP-1:
NADPH:
NO:
NOS:
nNOS:
iNOS:
eNOS:
nCEH:
OS:
PEG-SOD:
RCT:
RNS:
ROS:
Apolipoprotein E
(6R-)5,6,7,8-tetrahydro-L-biopterin
Cholesterol esters
1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrr
3-carboxyl-2,2,5,5-tetramethyl-1-pyrrolidinyloxy
Diethyldithiocarbamic acid. Sodium salt. Trihydrate
Electron Spin Resonance
Flavin adenine dinucleotide
Fatty acids
Free cholesterol
Flavin mononucleotide
Krebs Hepes Buffer
Low density lipoprotein
Mitogene-activated protein
Monocyte Chemotactic Protein 1
Nicotinamide-adenine-dinucleotide phosphate
Nitric oxide
Nitric oxide synthases
neuronal NOS
inducible NOS
endothelial NOS
Neutral cholesterol ester hydrolase
Oxidative stress
Pegulated Superoxide Dismutase
Reverse cholesterol transport
Reactive nitrogen species
Reactive oxygen species
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SRs: Scavenger receptors
TNF-α:
VSMC:
1400W:
Tumor necosis factor-α
Vascular smooth muscle cell
N-(3-aminomethyl) benzyl-acetamidine
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